fingolimod hydrochloride has been researched along with teriflunomide in 89 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (teriflunomide) | Trials (teriflunomide) | Recent Studies (post-2010) (teriflunomide) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 561 | 50 | 417 |
| Protein | Taxonomy | fingolimod hydrochloride (IC50) | teriflunomide (IC50) |
|---|---|---|---|
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Mus musculus (house mouse) | 0.1213 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.388 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.3 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.3 | |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | 0.6295 | |
| Stromal interaction molecule 1 | Homo sapiens (human) | 4.3 | |
| Dihydroorotate dehydrogenase | Plasmodium falciparum (malaria parasite P. falciparum) | 3.9 | |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Rattus norvegicus (Norway rat) | 0.0172 | |
| Calcium release-activated calcium channel protein 1 | Homo sapiens (human) | 4.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (4.49) | 29.6817 |
| 2010's | 60 (67.42) | 24.3611 |
| 2020's | 25 (28.09) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, JY | 1 |
| Borriello, G; Cefaro, LA; Gasperini, C; Pozzilli, C; Prosperini, L; Tosto, G | 1 |
| Hartung, HP; Kieseier, BC; Stüve, O; Wiendl, H | 1 |
| Gasperini, C; Ruggieri, S | 1 |
| Fontoura, P; Garren, H | 1 |
| Gold, R | 1 |
| Jadidi-Niaragh, F; Mirshafiey, A | 1 |
| Killestein, J; Polman, CH; Rudick, RA | 1 |
| Graham-Rowe, D | 1 |
| Ais-Larisgoitia, A; de Lorenzo-Pinto, A; Rodríguez-González, CG | 1 |
| Bandichhor, R; Iqbal, J; Mulakayala, N; Oruganti, S; Rao, P | 1 |
| Fox, RJ | 1 |
| Agarwal, S; Deniz, B; Fox, RJ; Havrdova, E; Hutchinson, M; Kurukulasuriya, NC; Sarda, SP; Siddiqui, MK; Taneja, A | 1 |
| Alwan, S; Dahlgren, L; Lu, E; Sadovnick, AD; Synnes, A; Tremlett, H; Wang, BW | 1 |
| Weinstock-Guttman, B | 1 |
| Sorensen, PS | 1 |
| di Nuzzo, L; Nasca, C; Nicoletti, F; Orlando, R | 1 |
| Carrithers, MD | 1 |
| Bridel, C; Lalive, PH | 1 |
| McDonald, EA; Sedal, L; Wilson, IB | 1 |
| Moses, H | 1 |
| Bergvall, N; Cutter, G; Giovannoni, G; Nixon, R; Sfikas, N; Tomic, D | 1 |
| Thomas, RH; Wakefield, RA | 1 |
| Carreón-Guarnizo, E; Hernández-Clares, R; Meca-Lallana, JE | 1 |
| Aloi, JJ; English, C | 1 |
| Bagnato, F; Pawate, S | 1 |
| Cocco, E; Coghe, GC; Fenu, G; Frau, J; Lorefice, L; Marrosu, MG | 1 |
| Cocco, E; Coghe, GC; Fenu, G; Frau, F; Lorefice, L; Marrosu, MG | 1 |
| Harel, A; Lublin, F; Straus Farber, R | 1 |
| Aktas, O; Hartung, HP; Ingwersen, J | 1 |
| Iljicsov, A; Pál, Z; Simó, M | 1 |
| Kretzschmar, B; Pellkofer, H; Weber, MS | 1 |
| Habibi, M; Kuttab, HM | 1 |
| Weinshenker, BG; Wingerchuk, DM | 1 |
| Chard, D; Chataway, J; Trip, A | 1 |
| Dive-Pouletty, C; Freedman, MS; Hass, S; Leist, TP; Miller, AE; Montalban, X; Thangavelu, K | 1 |
| Tyor, WR; Vargas, DL | 1 |
| Fischetti, VA; Rumah, KR; Vartanian, TK | 1 |
| Bergamaschi, R; Boiocchi, C; Cuccia, M; Mallucci, G; Osera, C; Pascale, A; Pistono, C | 1 |
| Miller, A; Staun-Ram, E | 1 |
| Berve, K; Groh, J; Martini, R | 1 |
| Cooper, JD; Nelvagal, HR | 1 |
| Herrera, V; Johnson, KM; Ko, JJ; Lin, F; Zhou, H | 1 |
| Bramanti, P; Guarnera, C; Mazzon, E | 1 |
| Carlini, G; Cerqua, R; Danni, M; Lattanzi, S; Provinciali, L; Pulcini, A; Silvestrini, M; Taffi, R | 1 |
| Chataway, J; Doshi, A | 1 |
| Faissner, S; Gold, R | 1 |
| Rommer, PS; Zettl, UK | 1 |
| Beckmann, N; Doelemeyer, A; Dubost, V; Jivkov, M; Schmid, C; Smith, PA; Theil, D; Zurbruegg, S | 1 |
| Banzi, R; Bertele', V; Garattini, S; Gerardi, C; Rossi, S | 1 |
| Ahn, SW; Cho, JY; Huh, SY; Hyun, JW; Kim, BJ; Kim, HJ; Kim, SH; Kim, W; Lee, SH; Park, MS | 1 |
| Mitsikostas, DD; Papadopoulos, D | 1 |
| Bergmann, A; Braune, S; Freudensprung, U; Grimm, S; Hyde, R; Pellegrini, F; van Hövell, P | 1 |
| Babb, J; Carraro, M; Hou, Q; Jhaveri, M; Livingston, T; Mendoza, JP; Nicholas, J; Ontaneda, D; Riester, K; Zhou, J | 1 |
| Carruthers, R; Evans, C; Kingwell, E; Marrie, RA; Setayeshgar, S; Tremlett, H; Zhang, T; Zhu, F | 1 |
| Chitnis, T; Choudhry, NK; Desai, RJ; Gagne, JJ; Hurley, E; Mahesri, M; Matlin, OS; Minden, S; Shrank, WH; Spettell, CM; Tong, A | 1 |
| Cheong, WL; Yoon, EL | 1 |
| Alroughani, R; Ampapa, R; Bergamaschi, R; Boz, C; Butler, E; Butzkueven, H; Duquette, P; Ferraro, D; Girard, M; Grammond, P; Grand'Maison, F; Granella, F; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kappos, L; Karabudak, R; Kubala Havrdova, E; Kuhle, J; Lechner-Scott, J; Lugaresi, A; McCombe, PA; Onofrj, M; Ozakbas, S; Pesch, VV; Prat, A; Prevost, J; Pucci, E; Ramo-Tello, C; Sánchez-Menoyo, JL; Shaygannejad, V; Slee, M; Sola, P; Solaro, C; Spelman, T; Spitaleri, D; Terzi, M; Trojano, M; Turkoglu, R; Van Wijmeersch, B; Vucic, S; Yamout, B | 1 |
| Duquette, P; Haddad, P; Mouallif, S; Nakhaipour, HR; Schecter, R; Yeung, M | 1 |
| Harding, K; Hrastelj, J; Joseph, F; Pickersgill, T; Rimmer, A; Robertson, N; Tallantyre, E; Tomassini, V; Wardle, M; Williams, O; Willis, M | 1 |
| Alonso-Magdalena, L; Dangond, F; Galazka, A; Martinelli, V; Pfleger, C; Phillips, L; Rieckmann, P; Vermersch, P | 1 |
| Berger, T; Enzinger, C; Guger, M; Kalcher, S; Kraus, J; Kvas, E; Leutmezer, F | 2 |
| Al Khedr, A; Barbin, L; Berger, E; Bourre, B; Brassat, D; Brochet, B; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Clavelou, P; De Sèze, J; Debouverie, M; Debroucker, T; Defer, G; Edan, G; Foucher, Y; Gout, O; Guennoc, AM; Heinzlef, O; Labauge, P; Labeyrie, C; Laplaud, DA; Lebrun-Frenay, C; Leray, E; Lubetzki, C; Magy, L; Maubeuge, N; Michel, L; Moreau, T; Nifle, C; Papeix, C; Patry, I; Pelletier, J; Rollot, F; Stankoff, B; Thouvenot, E; Tourbah, A; Vermersch, P; Vukusic, S; Wahab, A; Wiertlewski, S | 1 |
| Akçalı, A; Akman, G; Altintas, A; Altunrende, B; Balcı, BP; Boz, C; Demirkıran, M; Efendi, H; Ekmekci, Ö; Kale, N; Karabudak, R; Karahan, SZ; Köseoğlu, M; Kurne, A; Ozakbas, S; Özer, B; Sevim, S; Soysal, A; Terzi, M; Turan, ÖF; Turkoglu, R; Yüceyar, N | 1 |
| Bensimon, AG; Conway, D; Cox, GM; Herrera, V; Macheca, M; Peeples, M; Vieira, MC | 1 |
| Arlauskienė, A; Laužikienė, D; Ramašauskaitė, D; Varytė, G; Zakarevičienė, J | 1 |
| Bowen, JD; Brink, J; Brown, TR; Lucassen, EB; Repovic, P; Smoot, K; Wundes, A | 1 |
| Azimi, AR; Nourbakhsh, B; Safavi, F | 1 |
| Amor, S; Baker, D; Giovannoni, G; Kang, AS; Schmierer, K | 1 |
| Angarano, G; Bavaro, DF; Bollo, L; Guerra, T; Iaffaldano, P; Monno, L; Paolicelli, D; Saracino, A; Trojano, M | 1 |
| Ahmed, SF; Alroughani, R; Ibrahim Ismail, I; Salama, S | 1 |
| Derfuss, T; Fischer-Barnicol, B; Kappos, L; Kuhle, J; Lorscheider, J; Oechtering, J | 1 |
| Carruthers, R; Evans, C; Kingwell, E; Marrie, RA; Tremlett, H; Walld, R; Zhang, T; Zhu, F | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
| Callegari, I; Derfuss, T; Galli, E | 1 |
| Espinosa-Rosso, R; Gil-Bernal, R; Gómez-Gómez, C; González-Caballero, JL | 1 |
| Awan, S; Eckert, SP; Farooq, O; Jakimovski, D; Weinstock-Guttman, B | 1 |
| Cano, S; Elliott, E; Jivraj, F; Kang, S; Kapadia, S; Reedie, S; Rock, M; Strzok, S | 1 |
| Haug, U; Kollhorst, B; Platzbecker, K; Wentzell, N | 1 |
| Calabrese, P; Chiavi, D; Dressel, H; Haag, C; Horn, AB; Kamm, CP; Kaufmann, M; Pot, C; Sieber, C; von Wyl, V; Zecca, C | 1 |
| Comabella, M; Fissolo, N; Gutierrez, L; Montalban, X; Pappolla, A; Perez-Hoyos, S; Rio, J; Sanchez, A; Villar, LM | 1 |
| Al-Asmi, A; Alroughani, R; Altintas, A; Ampapa, R; Blanco Morgado, Y; Butzkueven, H; Gerlach, O; Hodgkinson, S; Horakova, D; Kalincik, T; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; Oh, J; Ozakbas, S; Patti, F; Sanchez-Menoyo, JL; Soysal, A; Spelman, T; Spitaleri, D; Terzi, M; Tundia, N; Van Der Walt, A; van Pesch, V; Wong, SL; Yamout, B | 1 |
| Aparasu, RR; Earla, JR; Hutton, GJ; Johnson, ML; Li, J | 1 |
| Aguera-Morales, E; Al-Asmi, A; Al-Harbi, TM; Alroughani, R; Altintas, A; Ampapa, R; Bergamaschi, R; Boz, C; Butzkueven, H; Cartechini, E; Castillo-Trivino, T; Csepany, T; de Gans, K; Diouf, I; Duquette, P; Eichau, S; Ferraro, D; Gerlach, O; Gouider, R; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Hodgkinson, S; Horakova, D; Hughes, S; Iuliano, G; Kalincik, T; Kappos, L; Karabudak, R; Kubala Havrdova, E; Laureys, G; Lechner-Scott, J; Lugaresi, A; Malpas, CB; McCombe, PA; McGuigan, C; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Roos, I; Sa, MJ; Sánchez-Menoyo, JL; Sempere, AP; Sharmin, S; Shaw, C; Shaygannejad, V; Sidhom, Y; Slee, M; Sola, P; Solaro, C; Stuart, EA; Terzi, M; Treviño Frenk, I; van der Walt, A; Vucic, S; Yamout, B | 1 |
| Engin, E; Günal, D; Sünter, G; Vural, E; Yıldırım, KA | 1 |
| Axelsson, M; Brandt, AF; Carlin, G; Gafvelin, G; Grönlund, H; Hessa, T; Högelin, KA; Khademi, M; Kockum, I; Lycke, J; Malmeström, C; Olsson, T; Piehl, F; Rabenstein, M; Thomas, OG | 1 |
| Ahle, G; Bigaut, K; Collongues, N; Courtois, S; de Seze, J; Dentel, C; Fickl, A; Fleury, M; Gaultier, C; Kolitsi, I; Kremer, L; Lanotte, L; Moreau, A; Mostoufizadeh, S; Sellal, F | 1 |
| Benedetti, MD; Capobussi, M; Castellini, G; Featherstone, R; Filippini, G; Frau, S; Gonzalez-Lorenzo, M; Lucenteforte, E; Perduca, V; Tramacere, I; Virgili, G | 1 |
42 review(s) available for fingolimod hydrochloride and teriflunomide
| Article | Year |
|---|---|
Emerging oral drugs for multiple sclerosis.
Topics: Administration, Oral; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2008 |
New oral drugs for multiple sclerosis.
Topics: Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
Multiple sclerosis therapies: molecular mechanisms and future.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Crotonates; Daclizumab; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Mice; Multiple Sclerosis; Myelin Basic Protein; Nitriles; Peptide Fragments; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Vaccines, DNA | 2010 |
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Topics: Administration, Oral; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Therapeutic approach to multiple sclerosis by novel oral drug.
Topics: Administration, Oral; Cladribine; Crotonates; Diterpenes; Epoxy Compounds; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Patents as Topic; Phenanthrenes; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Oral treatment for multiple sclerosis.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
[Emerging therapies for multiple sclerosis].
Topics: 4-Aminopyridine; Administration, Oral; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Cladribine; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Young Adult | 2013 |
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
Topics: Cladribine; Crotonates; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Molecular Structure; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Small Molecule Libraries; Sphingosine; Toluidines | 2013 |
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Topics: Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Randomized Controlled Trials as Topic; Recurrence; Sphingosine; Toluidines | 2014 |
A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Multiple Sclerosis; Nitriles; Pregnancy; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Propylene Glycols; Sphingosine; Toluidines | 2014 |
An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase III as Topic; Crotonates; Daclizumab; Drug Approval; Female; Fingolimod Hydrochloride; Forecasting; Humans; Hydroxybutyrates; Immunoglobulin G; Injections, Intramuscular; Injections, Subcutaneous; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Patient Safety; Prognosis; Propylene Glycols; Severity of Illness Index; Sphingosine; Toluidines; Treatment Outcome | 2013 |
New management algorithms in multiple sclerosis.
Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal, Humanized; Clinical Protocols; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Peptides; Propylene Glycols; Sphingosine; Toluidines | 2014 |
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immune System; Multiple Sclerosis; NF-E2-Related Factor 2; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2014 |
Update on disease-modifying treatments for multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Quality of Life; Rituximab; Toluidines; Treatment Outcome | 2014 |
Update on multiple sclerosis treatments.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Sphingosine; Toluidines | 2014 |
Current management of relapsing-remitting multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Risk Assessment; Sphingosine; Toluidines | 2014 |
Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Approval; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2015 |
[Oral treatments in multiple sclerosis].
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2014 |
New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Drug Approval; Drug Costs; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Nitriles; Polyethylene Glycols; Toluidines; United States; United States Food and Drug Administration | 2015 |
Newer agents in the treatment of multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Toluidines; Treatment Outcome | 2015 |
Oral agents in multiple sclerosis.
Topics: Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Drug Approval; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Medication Adherence; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines | 2015 |
Induction and escalation therapies in multiple sclerosis.
Topics: Animals; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Induction Chemotherapy; Interferon-beta; Maintenance Chemotherapy; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Randomized Controlled Trials as Topic; Toluidines; Treatment Outcome | 2015 |
Novel Agents for Relapsing Forms of Multiple Sclerosis.
Topics: Adjuvants, Immunologic; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Nitriles; Recurrence; Toluidines | 2016 |
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Toluidines | 2016 |
[Oral disease-modifying agents in relapsing-remitting multiple sclerosis].
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines | 2015 |
The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Topics: Animals; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Quinolones; Toluidines | 2016 |
Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
Topics: Academic Medical Centers; Crotonates; Disease Management; Fingolimod Hydrochloride; Health Systems Plans; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Pharmacy Service, Hospital; Toluidines | 2016 |
Disease modifying therapies for relapsing multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Substitution; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Injections; Interferon-beta; Magnetic Resonance Imaging; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Toluidines | 2016 |
Update on disease-modifying therapies for multiple sclerosis.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Approval; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Infusions, Intravenous; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Polyomavirus Infections; Recurrence; Toluidines; Treatment Outcome; Tumor Virus Infections; United States; United States Food and Drug Administration | 2017 |
What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
Topics: Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunogenetics; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Toluidines | 2017 |
Effector and regulatory B cells in Multiple Sclerosis.
Topics: Alemtuzumab; Animals; B-Lymphocyte Subsets; B-Lymphocytes, Regulatory; Crotonates; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Rituximab; Toluidines | 2017 |
Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines | 2017 |
Multiple sclerosis, a treatable disease .
Topics: Adjuvants, Immunologic; Alemtuzumab; Crotonates; Demyelinating Diseases; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Toluidines | 2017 |
Oral Therapies for Multiple Sclerosis.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Quinolones; Sphingosine 1 Phosphate Receptor Modulators; Toluidines | 2019 |
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
Topics: Alemtuzumab; Cladribine; Crotonates; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Neoplasms; Nitriles; Toluidines | 2018 |
Preapproval and postapproval evidence on drugs for multiple sclerosis.
Topics: 4-Aminopyridine; Alemtuzumab; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Development; European Union; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Polyethylene Glycols; Recurrence; Toluidines; Treatment Outcome | 2018 |
Adherence to oral disease-modifying therapy in multiple sclerosis patients: A systematic review.
Topics: Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Medication Adherence; Multiple Sclerosis; Nitriles; Toluidines | 2019 |
Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prospective Studies; Rituximab; Toluidines | 2020 |
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Betacoronavirus; CD8-Positive T-Lymphocytes; Cladribine; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Deprescriptions; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immune Evasion; Immunity, Innate; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Lymphopenia; Macrophages; Monocytes; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Toluidines | 2020 |
Update on treatment in multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Algorithms; Antibodies, Monoclonal, Humanized; Cladribine; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Indans; Interferon-beta; Male; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Oxadiazoles; Pregnancy; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Toluidines | 2021 |
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.
Topics: Antibodies, Monoclonal; Child; Crotonates; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Prognosis; Sphingosine 1 Phosphate Receptor Modulators; Toluidines | 2022 |
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Topics: Adolescent; Adult; Alemtuzumab; Azathioprine; Cladribine; Daclizumab; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Immunotherapy; Interferon beta-1a; Interferon beta-1b; Male; Multiple Sclerosis; Natalizumab; Network Meta-Analysis; Rituximab; Young Adult | 2023 |
2 trial(s) available for fingolimod hydrochloride and teriflunomide
| Article | Year |
|---|---|
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Crotonates; Dimethyl Fumarate; Disability Evaluation; Disease Progression; Evidence-Based Medicine; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Numbers Needed To Treat; Recurrence; Severity of Illness Index; Toluidines; Treatment Outcome | 2016 |
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pregnancy; Recurrence | 2023 |
45 other study(ies) available for fingolimod hydrochloride and teriflunomide
| Article | Year |
|---|---|
Non-specific anti-proliferative effect of FTY720, a derivative of fungal metabolite from Iscaria sinclarii.
Topics: Aniline Compounds; Animals; Antibiotics, Antineoplastic; Cell Proliferation; Crotonates; Cyclosporine; Fingolimod Hydrochloride; Fungi; Hydroxybutyrates; Immunity, Cellular; Immunosuppressive Agents; Interleukin-2; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nitric Oxide; Nitriles; Propylene Glycols; Sphingosine; T-Lymphocytes; Tetrazolium Salts; Thiazoles; Toluidines; Tumor Necrosis Factor-alpha | 2008 |
The future of multiple sclerosis therapy.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Injections, Intravenous; Injections, Subcutaneous; Interferon-beta; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
Drugs: An injection of hope.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2012 |
In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Interferons; Multiple Sclerosis; Natalizumab; Nitriles; Peptides; Propylene Glycols; Sphingosine; Toluidines | 2013 |
Recognizing and overcoming potential barriers to oral medications for MS.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Sphingosine; Toluidines | 2014 |
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Adult; Crotonates; Dimethyl Fumarate; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Outcome Assessment, Health Care; Patient Acuity; Randomized Controlled Trials as Topic; Recurrence; Toluidines | 2014 |
New oral drugs for the treatment of multiple sclerosis.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Medication Therapy Management; Multiple Sclerosis; Nitriles; Toluidines; United Kingdom | 2016 |
Oral Multiple Sclerosis Drugs Inhibit the
Topics: Anti-Bacterial Agents; Clostridium perfringens; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Hydroxybutyrates; Microbial Sensitivity Tests; Nitriles; Toluidines | 2017 |
Fingolimod and Teriflunomide Attenuate Neurodegeneration in Mouse Models of Neuronal Ceroid Lipofuscinosis.
Topics: Adolescent; Adult; Aminopeptidases; Animals; Axons; Brain; Child; Crotonates; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Disease Models, Animal; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Male; Membrane Glycoproteins; Mice; Mice, Knockout; Molecular Chaperones; Neuronal Ceroid-Lipofuscinoses; Neurons; Nitriles; Serine Proteases; T-Lymphocyte Subsets; Thiolester Hydrolases; Toluidines; Tripeptidyl-Peptidase 1; Young Adult | 2017 |
Progress toward Fulfilling the Potential of Immunomodulation in Childhood Neurodegeneration?
Topics: Animals; Crotonates; Disease Models, Animal; Fingolimod Hydrochloride; Hydroxybutyrates; Immunomodulation; Mice; Neurodegenerative Diseases; Neuronal Ceroid-Lipofuscinoses; Nitriles; Toluidines | 2017 |
Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Topics: Adolescent; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Medicare; Medication Adherence; Multiple Sclerosis; Nitriles; Retrospective Studies; Toluidines; United States | 2017 |
Persistence to oral disease-modifying therapies in multiple sclerosis patients.
Topics: Adult; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Retrospective Studies; Statistics, Nonparametric; Toluidines; Treatment Outcome | 2017 |
Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
Topics: Animals; Atrophy; Brain; Brain-Derived Neurotrophic Factor; Crotonates; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Hydroxybutyrates; Immunosuppressive Agents; Interleukin-17; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Nitriles; Toluidines | 2018 |
Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
Topics: Adolescent; Adult; Crotonates; Demyelinating Diseases; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Nitriles; Oligoclonal Bands; Optic Neuritis; Quinolones; Reproducibility of Results; Republic of Korea; Sensitivity and Specificity; Time Factors; Toluidines; Young Adult | 2019 |
Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Young Adult | 2018 |
Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Topics: Adult; Cohort Studies; Crotonates; Delayed-Action Preparations; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Germany; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Interferons; Male; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Registries; Toluidines; Treatment Outcome | 2018 |
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Topics: Administration, Oral; Adolescent; Adult; Aged; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Secondary Prevention; Toluidines; Treatment Outcome; United States; Young Adult | 2019 |
Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
Topics: Adult; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Nitriles; Toluidines | 2019 |
Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
Topics: Administration, Oral; Adult; Cohort Studies; Crotonates; Dimethyl Fumarate; Drug Prescriptions; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Insurance, Pharmaceutical Services; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Nitriles; Patient Preference; Retrospective Studies; Toluidines; United States; Young Adult | 2019 |
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Topics: Adult; Cohort Studies; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propensity Score; Proportional Hazards Models; Recurrence; Toluidines | 2019 |
A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
Topics: Canada; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Insurance Claim Review; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Patient Compliance; Retrospective Studies; Toluidines | 2019 |
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
Topics: Activities of Daily Living; Adolescent; Adult; Alemtuzumab; Cohort Studies; Crotonates; Dimethyl Fumarate; Disease Progression; Early Medical Intervention; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferons; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Retrospective Studies; Toluidines; Treatment Outcome; Young Adult | 2019 |
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Topics: Alemtuzumab; Cladribine; Crotonates; Decision Support Techniques; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Recurrence; Risk Assessment; Toluidines | 2019 |
Real-life use of oral disease-modifying treatments in Austria.
Topics: Administration, Oral; Adult; Austria; Cohort Studies; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propensity Score; Recurrence; Registries; Toluidines | 2019 |
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
Topics: Adult; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Treatment Outcome | 2019 |
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
Topics: Adult; Crotonates; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Outcome Assessment, Health Care; Propensity Score; Retrospective Studies; Secondary Prevention; Severity of Illness Index; Toluidines | 2019 |
Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
Topics: Adolescent; Adult; Crotonates; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Retrospective Studies; Time-to-Treatment; Toluidines; Treatment Failure; United States; Young Adult | 2020 |
Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Topics: Administration, Oral; Adult; Austria; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Outcome Assessment, Health Care; Registries; Severity of Illness Index; Toluidines | 2020 |
COVID-19 in MS: Initial observations from the Pacific Northwest.
Topics: Adult; Aged; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunocompromised Host; Immunosuppressive Agents; Interferons; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Northwestern United States; Nursing Homes; Oregon; Pandemics; Pneumonia, Viral; Severity of Illness Index; Toluidines; Travel; Washington | 2020 |
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Topics: Adult; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Disease Susceptibility; Dyspnea; Epidemics; Female; Fever; Fingolimod Hydrochloride; Glatiramer Acetate; Hospitalization; Humans; Hydroxybutyrates; Immunocompromised Host; Immunologic Factors; Intensive Care Units; Interferons; Iran; Lung; Lymphocyte Depletion; Male; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Severity of Illness Index; Toluidines; Tomography, X-Ray Computed | 2020 |
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
Topics: Adult; COVID-19; Crotonates; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Nitriles; SARS-CoV-2; Seroconversion; Toluidines | 2020 |
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Child; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunologic Factors; Interferon-beta; Kuwait; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Recurrence; Rituximab; SARS-CoV-2; Surveys and Questionnaires; Telephone; Toluidines; Young Adult | 2020 |
Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.
Topics: Adjuvants, Immunologic; Antiviral Agents; Crotonates; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Interferon beta-1a; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Toluidines | 2021 |
Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study.
Topics: Administration, Oral; Adult; Crotonates; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Prospective Studies; Toluidines | 2021 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |
Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Topics: Adult; Aged; Alemtuzumab; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasms; Nitriles; Outpatients; Proportional Hazards Models; Risk Factors; Smoking; Spain; Toluidines | 2021 |
The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
Topics: Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Qualitative Research; Recurrence; Toluidines | 2022 |
Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany.
Topics: Child; Cladribine; Cross-Sectional Studies; Drug Utilization; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Infant, Newborn; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy | 2022 |
Electronic Health Diary Campaigns to Complement Longitudinal Assessments in Persons With Multiple Sclerosis: Nested Observational Study.
Topics: Adult; Crotonates; Electronics; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Interferon beta-1a; Male; Medical Records; Middle Aged; Multiple Sclerosis; Nitriles; Quality of Life; Toluidines | 2022 |
Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis.
Topics: Chemokine CXCL13; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Retrospective Studies; Tablets | 2023 |
Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.
Topics: Adult; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Medication Adherence; Multiple Sclerosis; Retrospective Studies | 2023 |
Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Universities | 2023 |
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Topics: Adaptive Immunity; Alemtuzumab; Antibodies; Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Interferon-gamma; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Vaccination | 2023 |
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study.
Topics: Adolescent; Child; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |